Regulus Therapeutics
RGLS
#6934
Rank
ยฃ0.42 B
Marketcap
ยฃ6.15
Share price
0.00%
Change (1 day)
423.77%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -ยฃ36.82 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -ยฃ34.84 Million a decrease over its 2023 earnings that were of -ยฃ22.2 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -ยฃ36.82 Million5.67%
2024 -ยฃ34.84 Million56.97%
2023 -ยฃ22.2 Million6.51%
2022 -ยฃ20.84 Million2.53%
2021 -ยฃ20.33 Million93.59%
2020 -ยฃ10.5 Million-15.41%
2019 -ยฃ12.42 Million-64.46%
2018 -ยฃ34.92 Million-33.26%
2017 -ยฃ52.32 Million-13.98%
2016 -ยฃ60.83 Million44.77%
2015 -ยฃ42.02 Million-1.63%
2014 -ยฃ42.72 Million203.6%
2013 -ยฃ14.07 Million8.65%
2012 -ยฃ12.95 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
ยฃ5.80 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
ยฃ1.17 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ7.03 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ10.63 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
ยฃ7.46 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-ยฃ82.22 Million 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-ยฃ88.72 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
ยฃ0.43 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA